KR101049100B1 - 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법 - Google Patents

데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법 Download PDF

Info

Publication number
KR101049100B1
KR101049100B1 KR1020057001947A KR20057001947A KR101049100B1 KR 101049100 B1 KR101049100 B1 KR 101049100B1 KR 1020057001947 A KR1020057001947 A KR 1020057001947A KR 20057001947 A KR20057001947 A KR 20057001947A KR 101049100 B1 KR101049100 B1 KR 101049100B1
Authority
KR
South Korea
Prior art keywords
substituted
delete delete
compound
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057001947A
Other languages
English (en)
Korean (ko)
Other versions
KR20050083610A (ko
Inventor
요시오 하야시
제니퍼 그로드버그
마이클 팔라디노
Original Assignee
니리어스 파마슈티컬즈, 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니리어스 파마슈티컬즈, 인코퍼레이션 filed Critical 니리어스 파마슈티컬즈, 인코퍼레이션
Publication of KR20050083610A publication Critical patent/KR20050083610A/ko
Application granted granted Critical
Publication of KR101049100B1 publication Critical patent/KR101049100B1/ko
Assigned to 다롄 완춘 바이오테크놀로지 씨오., 엘티디. reassignment 다롄 완춘 바이오테크놀로지 씨오., 엘티디. 권리의 전부이전등록 Assignors: 니리어스 파마슈티컬즈, 인코퍼레이션
Assigned to 비욘드스프링 파마수티컬스, 인코포레이티드. reassignment 비욘드스프링 파마수티컬스, 인코포레이티드. 권리의 전부이전등록 Assignors: 다롄 완춘 바이오테크놀로지 씨오., 엘티디.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020057001947A 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법 Expired - Lifetime KR101049100B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40107402P 2002-08-02 2002-08-02
US60/401,074 2002-08-02
US41112802P 2002-09-16 2002-09-16
US60/411,128 2002-09-16
US45006303P 2003-02-24 2003-02-24
US60/450,063 2003-02-24
PCT/US2003/024232 WO2004054498A2 (en) 2002-08-02 2003-08-01 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117006692A Division KR101184374B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법

Publications (2)

Publication Number Publication Date
KR20050083610A KR20050083610A (ko) 2005-08-26
KR101049100B1 true KR101049100B1 (ko) 2011-07-15

Family

ID=32600863

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057001947A Expired - Lifetime KR101049100B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법
KR1020117006692A Expired - Lifetime KR101184374B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117006692A Expired - Lifetime KR101184374B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법

Country Status (19)

Country Link
US (4) US7064201B2 (https=)
EP (1) EP1529044B1 (https=)
JP (1) JP4616649B2 (https=)
KR (2) KR101049100B1 (https=)
CN (1) CN100540548C (https=)
AT (1) ATE374767T1 (https=)
AU (1) AU2003302721B2 (https=)
BR (2) BR0313363A (https=)
CA (1) CA2494049C (https=)
CO (1) CO5721010A2 (https=)
DE (1) DE60316688T2 (https=)
DK (1) DK1529044T5 (https=)
ES (1) ES2295695T3 (https=)
IL (2) IL166628A0 (https=)
MX (1) MXPA05001217A (https=)
NZ (1) NZ538433A (https=)
PT (1) PT1529044E (https=)
WO (1) WO2004054498A2 (https=)
ZA (1) ZA200501616B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180027563A (ko) * 2015-07-13 2018-03-14 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
BRPI0017067B8 (pt) * 2000-01-18 2021-05-25 Beyondspring Pharmaceuticals Inc inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BR0313363A (pt) 2002-08-02 2005-08-09 Nereus Pharmaceuticals Inc Deidrofenilahistinas e seus análogos, e sua sìntese
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
NZ539735A (en) 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
EP1711487A1 (en) * 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US20090286838A1 (en) * 2004-12-06 2009-11-19 Newsouth Innovations Pty Limited Treatment for cancer
WO2006105051A2 (en) 2005-03-29 2006-10-05 Nereus Pharmaceuticals, Inc. Synthesis of diketopiperazines
JP2008024871A (ja) * 2006-07-24 2008-02-07 Fujifilm Corp インク組成物、インクジェット記録方法、印刷物、平版印刷版の製造方法、及び平版印刷版
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
JP2012509878A (ja) * 2008-11-21 2012-04-26 アイシス ファーマシューティカルズ， インコーポレーテッド ドセタキセルおよびアンチセンスオリゴヌクレオチドを含む、抗腫瘍併用療法
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
JP6411523B2 (ja) 2013-10-11 2018-10-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
AU2016219204B2 (en) * 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors
MX383691B (es) * 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
HK1249051A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗脑肿瘤的方法
CN106279039B (zh) * 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) * 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
CN107778297B (zh) * 2016-08-12 2021-11-19 深圳华大海洋科技有限公司 氘代脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法和应用
CN107011322B (zh) * 2016-08-12 2020-02-18 青岛海洋生物医药研究院股份有限公司 一种脱氢苯基阿夕斯丁类化合物的制备纯化方法
CN109563079B (zh) * 2016-08-12 2021-10-26 深圳华大海洋科技有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备纯化方法和应用
CN106565685B (zh) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
CN106565686B (zh) 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
AU2018236168B2 (en) 2017-03-13 2024-02-29 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
CN108658945B (zh) * 2017-03-31 2020-11-20 深圳海王医药科技研究院有限公司 一种微管蛋白抑制剂（vda-1）的a晶型
WO2019028144A1 (en) 2017-08-03 2019-02-07 Teva Pharmaceuticals Usa, Inc. SALTS AND FORMS IN THE SOLID STATE OF PLINABULIN
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
CN111018840B (zh) * 2017-10-25 2022-09-09 西南大学 3-咪唑取代的靛红唑醇类化合物及其制备方法和医药应用
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN108299399A (zh) * 2018-02-01 2018-07-20 深圳海王医药科技研究院有限公司 一种小分子免疫化合物的晶型、其制备方法和含有其的药物组合物
ES3060133T3 (en) * 2018-06-01 2026-03-25 Beyondspring Pharmaceuticals Inc Composition and method of treating cancer associated with egfr mutation
CN109030642B (zh) * 2018-06-26 2021-03-09 深圳海王医药科技研究院有限公司 一种脱氢苯基阿夕斯丁类似物及其异构体的测定方法
CN111840291B (zh) * 2020-07-14 2021-12-21 深圳海王医药科技研究院有限公司 一种在肿瘤治疗中具有增效作用的化合物的应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN117164560A (zh) * 2022-06-02 2023-12-05 上海旭成医药科技有限公司 哌嗪酮类化合物及其制备方法和用途
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
WO2024191805A1 (en) 2023-03-10 2024-09-19 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403790A1 (en) * 2000-01-18 2001-07-26 Nereus Pharmaceuticals, Inc. A cell division inhibitor and a production method thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) * 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
EP2201945B1 (en) * 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
PL342254A1 (en) 1998-01-29 2001-06-04 Aventis Pharm Prod Inc Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
PL343249A1 (en) * 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) * 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US6569556B2 (en) * 2001-01-29 2003-05-27 General Motors Corporation Cooling system for a battery pack
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BR0313363A (pt) * 2002-08-02 2005-08-09 Nereus Pharmaceuticals Inc Deidrofenilahistinas e seus análogos, e sua sìntese
EP1711487A1 (en) 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403790A1 (en) * 2000-01-18 2001-07-26 Nereus Pharmaceuticals, Inc. A cell division inhibitor and a production method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180027563A (ko) * 2015-07-13 2018-03-14 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물
KR102680823B1 (ko) * 2015-07-13 2024-07-03 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물

Also Published As

Publication number Publication date
CN1684955A (zh) 2005-10-19
BRPI0313363A8 (pt) 2019-01-02
US20060223822A1 (en) 2006-10-05
US7956058B2 (en) 2011-06-07
DK1529044T5 (da) 2008-04-21
WO2004054498A3 (en) 2004-11-25
NZ538433A (en) 2008-02-29
CO5721010A2 (es) 2007-01-31
DE60316688D1 (de) 2007-11-15
ATE374767T1 (de) 2007-10-15
US20060217553A1 (en) 2006-09-28
US7064201B2 (en) 2006-06-20
US20060223823A1 (en) 2006-10-05
DK1529044T3 (da) 2008-02-04
ES2295695T3 (es) 2008-04-16
ZA200501616B (en) 2005-11-30
MXPA05001217A (es) 2005-05-16
EP1529044B1 (en) 2007-10-03
BR0313363A (pt) 2005-08-09
HK1084388A1 (zh) 2006-07-28
KR20050083610A (ko) 2005-08-26
IL166628A (en) 2012-08-30
AU2003302721B2 (en) 2009-10-08
CA2494049A1 (en) 2004-07-01
JP2006511534A (ja) 2006-04-06
DE60316688T2 (de) 2008-07-17
US20050090667A1 (en) 2005-04-28
CN100540548C (zh) 2009-09-16
CA2494049C (en) 2011-10-18
JP4616649B2 (ja) 2011-01-19
WO2004054498A2 (en) 2004-07-01
PT1529044E (pt) 2008-01-14
AU2003302721A1 (en) 2004-07-09
EP1529044A2 (en) 2005-05-11
KR101184374B1 (ko) 2012-09-20
KR20110039500A (ko) 2011-04-18
US7674903B2 (en) 2010-03-09
HK1078080A1 (en) 2006-03-03
IL166628A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
KR101049100B1 (ko) 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법
US7919497B2 (en) Analogs of dehydrophenylahistins and their therapeutic use
US8129527B2 (en) Analogs of dehydrophenylahistins and their therapeutic use
KR101228104B1 (ko) 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법
US7935704B2 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ZA200607151B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN101633655B (zh) 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
HK1078080B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
HK1084388B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
MXPA06008810A (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080702

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100728

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110131

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100728

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110302

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110131

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110426

Appeal identifier: 2011101001727

Request date: 20110302

AMND Amendment
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110323

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110314

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110302

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20100928

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20110426

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20110404

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110707

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110708

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140702

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140702

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150617

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150617

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160616

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160616

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170616

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170616

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20180615

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190617

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190617

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200618

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210617

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20220615

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20240201

Termination category: Expiration of duration